AstraZeneca PLC
AZN: XLON (GBR)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
GBX 21,377.00 | Gbjd | Kfhgvbkbl |
Buoyed by Cancer Drugs and Robust Newer Drug Portfolio, AstraZeneca Posts Strong Q2
AstraZeneca reported solid second-quarter results slightly ahead of our projections, but we do not expect any major changes to our fair value estimate based on the minor outperformance. We continue to view AstraZeneca as fairly valued, with the stock price reflecting the solid sales growth outlook (8% five-year compound annual growth rate) driven by current and pipeline products that also support the firm’s wide moat.